Home » Newsletters » BioWorld Science

BioWorld Science

May 13, 2015

View Archived Issues

NO-donating bimatoprost shows preclinical efficacy reducing IOP

FDA designates Cidara's CD-101 IV as QIDP

Lilly and BioNTech form cancer immunotherapy collaboration

NAPs show promising sequence-independent antiviral activity

Retrophin introduces compounds for the treatment of neurodegeneration

Roche patents CYP11B2 inhibitors

Astellas to access Cyclenium's macrocycle drug discovery technologies

Roivant Sciences licenses nelotanserin from Arena Pharmaceuticals

Sumitomo Dainippon Pharma profiles progress of fourth quarter of fiscal 2014

Celprogen reveals pancreatic stem cell stimulator STEMC-7007

Data on REGN-844 for dry eye disease reported

PIM-447 shows potential for the treatment of MM

Merck & Co. discloses ROM-K channel blockers

Michael J. Fox Foundation acquires research tools from Imago

Dana-Farber, Syros Pharmaceuticals and Paraza Pharma jointly patent CDK7 inhibitors

Evofosfamide receives FDA fast track designation for pancreatic cancer

Shionogi prepares and tests ACC2 inhibitors

Astellas Pharma discloses GABA(B) positive allosteric modulators

Intravitreal CD34+ autologous bone marrow-derived cells safe in dry AMD patients

MorphoSys completes acquisition of Lanthio Pharma

FDA advisory committee recommends approval of Orkambi for cystic fibrosis

Preliminary phase I results of Ebola prime-boost vaccine regimen of MVA-BN Filo and AdVac

Takeda terminates phase III trial of alisertib in peripheral T-cell lymphoma

Fibrocell's FCX-007 receives rare pediatric disease designation from the FDA

FDA awards orphan drug designation to SemiAlloGen's approach to targeting glioblastoma

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...